Nykredit A S Acquires Shares of 235,332 Kenvue Inc. $KVUE

Key Points

• Nykredit A/S acquired 235,332 Kenvue shares in the second quarter, valued at approximately $4.5 million. Institutional investors collectively own 97.64% of the company.
• Analyst sentiment remains cautious, with a consensus “Hold” rating from MarketBeat and an average price target of $19.27; UBS recently lowered its target to $19.
• Kenvue reported quarterly revenue of $3.96 billion, up 3% year over year, but narrowly missed earnings estimates. The company announced a quarterly dividend of $0.21 per share, representing a 4.7% annualized yield.

Nykredit A S bought a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 235,332 shares of the company's stock, valued at approximately $4,497,000.

A number of other hedge funds have also recently added to or reduced their stakes in KVUE. Johnson Financial Group Inc. purchased a new position in Kenvue during the 2nd quarter worth $26,000. MV Capital Management Inc. purchased a new stake in Kenvue in the 4th quarter valued at approximately $28,000. CoreCap Advisors LLC increased its position in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock worth $29,000 after purchasing an additional 591 shares during the period. Reflection Asset Management acquired a new position in Kenvue during the fourth quarter worth $32,000. Finally, Bell Investment Advisors Inc acquired a new position in Kenvue during the second quarter worth $35,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on KVUE. Zacks Research downgraded Kenvue from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Kenvue in a research note on Friday, September 11th. UBS Group cut their price target on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a report on Tuesday, August 11th. Wall Street Zen cut shares of Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company's stock. According to data from MarketBeat, Kenvue presently has a consensus rating of "Hold" and a consensus price target of $19.27.

Kenvue Price Performance

NYSE:KVUE opened at $17.86 on Wednesday. The firm has a market cap of $34.31 billion, a price-to-earnings ratio of 20.53, a price-to-earnings-growth ratio of 1.62 and a beta of 0.46. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The company's 50-day moving average is $18.84 and its two-hundred day moving average is $18.19. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $20.13.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm had revenue of $3.96 billion for the quarter, compared to analysts' expectations of $3.97 billion. During the same quarter last year, the firm earned $0.29 earnings per share. The business's quarterly revenue was up 3.0% compared to the same quarter last year. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 2nd. Investors of record on Monday, September 21st will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 4.7%. The ex-dividend date of this dividend is Monday, September 21st. Kenvue's dividend payout ratio is 96.55%.

Kenvue Profile

Kenvue Inc is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.

The company's brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson's and Band-Aid in baby care and essential health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.